Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai Patents (Class 514/183)
  • Patent number: 10287262
    Abstract: The present invention provides compounds (n-3 PUFA derivatives) of formula (I): that modulate conditions associated with cardiac damage, especially cardiac arrhythmias.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: May 14, 2019
    Assignees: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN, BOARD OF REGENTS OF UNIVERSITY OF TEXAS SYSTEM
    Inventors: Wolf-Hagen Schunck, Gerd Wallukat, Robert Fischer, Cosima Arnold, Dominik N. Mueller, Narender Puli, John R. Falck
  • Patent number: 10273202
    Abstract: Described herein are nitroxyl progenitor compounds, and compositions including, and methods or generating, the compounds thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: April 30, 2019
    Assignee: The Johns Hopkins University
    Inventors: John P. Toscano, Christopher M. Pavlos, Preeya Kapur Boppana
  • Patent number: 10245276
    Abstract: The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: April 2, 2019
    Assignee: LABORATORIOS DEL DR. ESTEVE, S.A.
    Inventors: Carlos Ramon Plata Salaman, Nicolas Tesson
  • Patent number: 10238668
    Abstract: The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: March 26, 2019
    Assignee: LABORATORIOS DEL DR. ESTEVE, S.A.
    Inventors: Carlos Ramon Plata Salaman, Nicolas Tesson
  • Patent number: 10227610
    Abstract: Methods and compositions for increasing nuclease-mediated genomic modification using DNA repair inhibitors are provided.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: March 12, 2019
    Assignees: Sangamo Therapeutics, Inc., Sigma Aldrich Co LLC
    Inventors: Fuqiang Chen, Qiaohua Kang, Thomas Wechsler
  • Patent number: 10226455
    Abstract: Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof in an amount and formulation sufficient to inhibit or induce drug-sensitization in a parasite. The methods can comprise administering a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof to a parasite in an amount and formulation sufficient to inhibit or induce drug-sensitization in the parasite.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: March 12, 2019
    Assignee: The Texas A&M University System
    Inventors: James C. Sacchettini, Matthew W. Miller, Deeann Wallis, Nian E. Zhou, Theresa W. Fossum
  • Patent number: 10213507
    Abstract: The invention pertains to a formulation comprising magnetic nanoparticles (MENPs) conjugated to or mixed with a therapeutic cargo, the therapeutic cargo comprising an HIV inhibitor, an inhibitor of BACE-1 activity or expression, and a cocaine antagonist. In one embodiment, the formulation comprises WA, miR-107, and BD1063. The MENPs conjugated or mixed with the therapeutic cargo can be encapsulated within liposomes. The liposomes can be surface modified with an affinity ligand that targets the liposomes to the brain. The invention also pertains to a method of treating an HIV infection in a subject having cocaine addiction, by administering to the subject the formulation of the invention and applying to the subject magnetic forces to guide the MENPs across the blood brain barrier and into brain parenchyma and releasing the therapeutic cargo into the brain parenchyma by applying to the subject an alternating current.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: February 26, 2019
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Madhavan Nair, Sneham Tiwari, Adriana Yndart Arias
  • Patent number: 10211404
    Abstract: A high-performance organic electroluminescence device and an electronic equipment provided with the organic electroluminescence device are provided. Also, a compound for achieving the organic electroluminescence device and the electronic equipment is provided. Specifically, a compound having a specific structure having a triphenylene skeleton, an organic electroluminescence device using the compound and an electronic equipment provided with the organic electroluminescence device are provided.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: February 19, 2019
    Assignee: IDEMITSU KOSAN CO., LTD.
    Inventors: Masahiro Kawamura, Yumiko Mizuki, Hirokatsu Ito, Tomoharu Hayama, Tasuku Haketa
  • Patent number: 10208002
    Abstract: The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: February 19, 2019
    Assignee: Incyte Corporation
    Inventors: Andrew P. Combs, Eddy W. Yue
  • Patent number: 10189798
    Abstract: The present disclosure pertains to antimicrobial compounds that include silver (Ag) and an s-triazine ring with substitutions at nitrogen or carbon atoms of the s-triazine ring. In one example, the antimicrobial silver s-triazine may be readily incorporated in a variety of compositions and devices in both medical and non-medical settings. In another example, the said compounds may possess broad spectrum antimicrobial activity against bacteria, viruses, fungi and other microbes.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: January 29, 2019
    Assignee: MEDICAL TECHNOLOGY RESEARCH INC
    Inventor: Bhalchandra M. Karandikar
  • Patent number: 10188674
    Abstract: Pharmaceutical compositions adapted for the parenteral administration, including intravenous administration, of triazole containing macrolide antibiotics, and methods for their use in the treatment of bacterial, protozoal, and other infections are described herein.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: January 29, 2019
    Assignee: CEMPRA PHARMACEUTICALS, INC.
    Inventors: David E. Pereira, Sara Wu, Prabhavathi Fernandes
  • Patent number: 10166191
    Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: January 1, 2019
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
  • Patent number: 10160767
    Abstract: The present invention pertains to the field of pharmaceutical chemicals, and relates to a rapamycin derivative of Formula I, and a preparation method, pharmaceutical composition and use thereof. The compounds of the present invention overcome the defects of rapamycin in terms of water solubility and metabolic properties, and some of the compounds have an in vitro anti-tumor activity superior to rapamycin, have less toxicity to normal cells than rapamycin, and have very good druggability.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: December 25, 2018
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Wu Zhong, Song Li, Shuang Cao, Ruiyuan Cao, Junhai Xiao, Xinbo Zhou, Xingzhou Li
  • Patent number: 10155021
    Abstract: This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens. The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: December 18, 2018
    Assignee: Emergent Product Development Gaithersburg Inc.
    Inventors: Jutta Heim, Peter Schneider, Patrick Roussel, Daniel Milligan, Christian Bartels, Glenn Dale
  • Patent number: 10149889
    Abstract: The invention relates to pharmaceutical compositions comprising leukotoxin, including methods to treat lymphoma, and methods to diagnose lymphoma. The lymphoma includes lymphoma cells expressing activated LFA-1, and the leukotoxin binds to the activated LFA-1 on the lymphoma cells and destroys the lymphoma cells by apoptosis or necrosis, thereby treating said lymphoma.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: December 11, 2018
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventor: Scott Kachlany
  • Patent number: 10130610
    Abstract: In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof in an amount of 5% by mass or more, comprised is/are acetone, a polyoxyethylene alkyl (having 8 to 30 carbon atoms) ether, and/or a polyoxyethylene alkenyl (having 8 to 30 carbon atoms) ether. Provided is a preparation using a solvent other than crotamiton, propylene carbonate, and N-methyl-2-pyrrolidone as a solvent for solubilization and steric stabilization and having the following properties: 1) when a compound represented by the general formula (1) and/or a salt thereof has a stereoisomer, the amount of the stereoisomer of the compound and/or a salt thereof produced under a preservation condition of 60° C. for 3 weeks is 1% by mass or less with respect to the total mass of the compound and/or a salt thereof at the beginning of preservation; 2) the preparation is in a clear liquid state when preserved at a constant temperature of 20° C.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: November 20, 2018
    Assignees: Pola Pharma Inc., Nihon Nohyaku Co., Ltd.
    Inventors: Hirokazu Kobayashi, Eiko Kosugi, Nobuo Kubota
  • Patent number: 10117939
    Abstract: The present application provides pharmaceutical compositions comprising as the active medicinal ingredient nebivolol, a nebivolol analog or a pharmaceutically acceptable acid addition salt thereof and a wetting agent. The invention also relates to methods of preparing and using said compositions.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: November 6, 2018
    Assignee: Mylan Pharmaceuticals ULC
    Inventors: Mostafa Akbarieh, Fazal M. Mohideen, Shetal Shah
  • Patent number: 10100011
    Abstract: The present invention relates to a novel pentadienoyl piperidine derivative, a pharmaceutical composition containing the same for prevention or treatment of metabolic diseases, and a functional food composition using the same for improvement or relief of metabolic diseases. The pentadienoyl piperidine derivative of the present invention inhibits the differentiation of preadipocytes, reduces body weight, visceral fat, blood lipid levels, and blood glucose levels, improves a blood liver function index, and suppresses metabolic inflammation responses. Thus, ultimately, the derivative can be usefully used as a medicine or a functional food composition, which exhibits the preventive or therapeutic activity for metabolic diseases selected from the group consisting of obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: October 16, 2018
    Assignees: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY, SNU R&DB FOUNDATION
    Inventors: Tae Sun Park, Lak Shin Jeong
  • Patent number: 10072016
    Abstract: The present invention provides a compound having the structure: wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl, wherein two or more of R1, R2, R3, R4, or R5 are other than H; R6 is H, OH, or halogen; and B is a substituted or unsubstituted heterobicycle, wherein when R1 is CF3, R2 is H, R3 is F, R4 is H, and R5 is H, or R1 is H, R2 is CF3, R3 is H, R4 is CF3, and R5 is H, or R1 is Cl, R2 is H, R3 is H, R4 is F, and R5 is H, or R1 is CF3, R2 is H, R3 is F, R4 is H, and R5 is H, or R1 is CF3, R2 is F, R3 is H, R4 is H, and R5 is H, or R1 is Cl, R2 is F, R3 is H, R4 is H, and R5 is H, then B is other than or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: September 11, 2018
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Konstantin Petrukhin, Christopher Cioffi, Graham Johnson, Rando Allikmets, Emily Freeman, Ping Chen, Michael Conlon, Lei Zhu
  • Patent number: 10071058
    Abstract: Described are controlled-release solid dosage forms of mesalamine. In one aspect of the invention the controlled-release solid dosage forms of mesalamine are capsules comprising a plurality of coated mini-tablets. Another aspect of the invention relates to a method of treating a patient suffering from inflammatory bowel disease, comprising the step of administering to the patient a therapeutically effective amount of the solid dosage form. The invention also relates to methods of inducing remission of inflammatory bowel disease and maintaining remission of inflammatory bowel disease. In certain aspects, the inflammatory bowel disease is ulcerative colitis or Crohn's disease.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: September 11, 2018
    Assignee: Santarus, Inc.
    Inventors: Craig Michael Bowe, John Christopher Carter, Dana Elaine Moseson, Stephen Paul Levine
  • Patent number: 10064867
    Abstract: The disclosure relates to Compounds of Formula (1): and pharmaceutically acceptable salts thereof wherein Z1, Z2, Z3, Xa, Xb, Xc, Y, X2, and X4 are as defined herein, compositions comprising an effective amount of a Compound of Formula (1) or a pharmaceutically acceptable salt thereof, and methods to treat or prevent a condition, such as cancer which overexpresses Her-kinases, comprising administering to an patient in need thereof a therapeutically effective amount of a Compound of Formula (1) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: September 4, 2018
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Tony Taldone, Gabriela Chiosis
  • Patent number: 10058611
    Abstract: The present invention relates to a use of alpha-(8-quinolinyloxy) mono-substituted phthalocyanine zinc for the treatment of psoriasis. The use is suitable for various type of psoriasis by utilizing photodynamic therapy. The photosensitizer is used to treat psoriasis by utilizing laser wave length of 670 nm, with high light sensitivity, fast photobleaching, short time needed in protection from light, and avoiding potential toxic and side-effect of photochemistry therapy by using ultraviolet irradiation. The preparation used in the use of ?-(8-quinolinyloxy) mono-substituted phthalocyanine zinc for the treatment of psoriasis includes solution, cream, nanomicelle, microsphere etc, and mode of administration can be systemic or topical administration. The practicability of treating psoriasis by photodynamic therapy has been validated on cell and animal model. The use achieves perfect effect.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: August 28, 2018
    Assignee: BEIJING GUIQIANJIN MEDICAL SCIENCE AND TECHNOLOGY CO., LTD.
    Inventors: Hanqing Liu, Aiping Wang, Jinfeng Wei, Hongtao Jin, Qianaian Zhang, Ni Lin, Zhihuan Jiang, Xiaodan Yan, Ye Li, Jingyi Feng, Yingming Wang
  • Patent number: 10045995
    Abstract: The present invention relates to an epidithiodioxopiperazine derivative represented by the following Chemical Formula 1 or its reduced derivative; a method for preparing a compound represented by Chemical Formula 1 having improved intracellular permeability and mimicking the activity of 2-Cys-Prx in its reduced form in the cells; a pharmaceutical composition for preventing or treating vascular diseases comprising an epidithiodioxopiperazine compound or its derivatives or pharmaceutically acceptable salts thereof as an active ingredient; a drug delivery device for local administration including the pharmaceutical composition; and a pharmaceutical composition for inhibiting melanoma metastasis comprising the epidithiodioxopiperazine compound or its derivatives or pharmaceutically acceptable salts thereof as an active ingredient.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: August 14, 2018
    Assignee: EWHA University Industry-Collaboration Foundation
    Inventors: Sang Won Kang, Dong Hoon Kang, Doo Jae Lee
  • Patent number: 10023534
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein Q is: or; and X, R1a, R1b, R3, R4, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: July 17, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Scott Hunter Watterson, Andrew J. Tebben, Saleem Ahmad
  • Patent number: 10016431
    Abstract: The present invention relates to a method of treating a disease in a subject, comprising administering to a subject in need thereof a solid pharmaceutical composition biopterin derivatives.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: July 10, 2018
    Assignee: VASOPHARM GMBH
    Inventors: Peter Scheurer, Frank Tegtmeier, Reinhard Schinzel
  • Patent number: 10017522
    Abstract: Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a chemical library relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: July 10, 2018
    Assignee: PRISM BioLab Co., Ltd.
    Inventors: Takenao Odagami, Yuji Kogami, Hiroyuki Kouji
  • Patent number: 9988378
    Abstract: The present invention relates to the use of novel compounds of formula (I), wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: June 5, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Niala Bhagirath, Joshua Kennedy-Smith, Matthew C. Lucas, Fernando Padilla
  • Patent number: 9974593
    Abstract: Methods for treating erectile dysfunction with therapeutic neuromodulation and associated systems and methods are disclosed herein. Erectile dysfunction can be characterized by the inability to develop and/or maintain an erection during sexual arousal or activity. One aspect of the present technology is directed to methods that at least partially inhibit sympathetic neural activity in nerves innervating the penis of a patient. Sympathetic drive in the patient can thereby be reduced in a manner that treats the patient for erectile dysfunction. Sympathetic nerve activity can be modulated along afferent and/or efferent pathways. The modulation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly, e.g., a therapeutic assembly configured to use electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the nerves.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: May 22, 2018
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventor: Neil Barman
  • Patent number: 9957395
    Abstract: An antimicrobial coating system and method are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two of the cyclic groups may include quaternary ammonium moieties. In some embodiments, a method may include applying an antimicrobial coating to an oral surface, a surface of a construction substrate, a surface of a marine substrate, a surface of a medical device, or a surface of a personal care device. The protective coating may be antimicrobial. A protective coating may include antimicrobial bridged polycyclic compounds. Bridged polycyclic compounds may include quaternary ammonium compounds. Bridged polycyclic compounds based coating systems may impart self-cleaning properties to a surface (e.g., a tooth surface).
    Type: Grant
    Filed: September 17, 2012
    Date of Patent: May 1, 2018
    Assignee: AllAccem, Inc.
    Inventors: Jeffery A. Whiteford, William P. Freeman
  • Patent number: 9949971
    Abstract: Therapeutic combinations of a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the ?- and ?-isoforms and selective for both ?- and ?-isoforms, are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of (1) a PI3K-? inhibitor and a BTK inhibitor, (2) a JAK-2 inhibitor and a BTK inhibitor, or (3) a JAK-2 inhibitor, PI3K-? inhibitor, and BTK inhibitor, and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: April 24, 2018
    Assignee: Acerta Pharma B.V.
    Inventors: Ahmed Hamdy, Wayne Rothbaum, Raquel Izumi, Brian Lannutti, Todd Covey, Roger Ulrich, Dave Johnson, Tjeerd Barf, Allard Kaptein
  • Patent number: 9944610
    Abstract: The present disclosure relates to a novel active compound having the formula Ia: solid preparations, uses and methods for the treatment or prevention of respiratory diseases comprising said compound as well as process of preparation thereof.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: April 17, 2018
    Assignee: UNIVERSITÉ LAVAL
    Inventors: Evelyne Israel-Assayag, Pierre Lavallee, Yvon Cormier, Bildad Nyambura
  • Patent number: 9937194
    Abstract: Described herein are compounds and pharmaceutical compositions useful for treating inflammatory diseases.
    Type: Grant
    Filed: August 28, 2012
    Date of Patent: April 10, 2018
    Assignee: Cempra Pharmaceuticals, Inc.
    Inventors: Prabhavathi Fernandes, David E. Pereira
  • Patent number: 9926304
    Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: March 27, 2018
    Assignee: Impact Therapeutics, Inc.
    Inventors: Sui Xiong Cai, Ye Edward Tian, Haijun Dong, Qingbing Xu, Lizhen Wu, Lijun Liu, Yangzhen Jiang, Qingli Bao, Guoxiang Wang, Feng Yin, Chengyun Gu, Xiuhua Hu, Xiaozhu Wang, Sishun Kang, Shengzhi Chen
  • Patent number: 9926268
    Abstract: Disclosed is a new method for preparing an azetidinone compound represented by formula (I). The carboxylic ketoester represented by formula (II) serves as the raw material and is subjected to Grignard addition, stereoselective dehydration, ester group reduction, hydroxyl group protection, addition with imine after condensation with a chiral auxiliary, cyclization and deprotection to obtain the compound represented by formula (I). The present invention has advantages of easily available raw material, a few synthetic steps, simple operation, high yield, good stereoselectivity and low cost, and can be used for industrial production.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: March 27, 2018
    Assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Hua Bai, Xuyang Zhao, Yuncai Zhang, Xufei Li, Yong Zhang, Dezhou Xu, Li Zhang, Xiaojie Xu, Qifeng Zhu, Xiaoming Wang, Zhiqing Yang, Zehua Zhong, Jian Zhang
  • Patent number: 9920027
    Abstract: Provided are 4?-O substituted isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: March 20, 2018
    Assignee: Celgene Corporation
    Inventors: Alexander L. Ruchelman, George W. Muller, Hon-Wah Man, Roger Shen-Chu Chen
  • Patent number: 9913849
    Abstract: Provided herein are prostaglandin F2alpha analog compositions and methods for treating migraines by topical administration. The method involves administering topically to a subject in need thereof a composition including a prostaglandin F2apha analog or pharmaceutically acceptable salt thereof, in an amount effective to treat migraine. The treatment may be administered prophylactically or therapeutically. Topical administration is to the epidermis, conjunctival surface or other mucous membranes, typically to a nail, the skin, the hair, the surface of the eye or the inner surface of the eyelid, and the like. The prostaglandin F2a analog can be latanoprost, isopropyl unoprostone, bimatoprost, travoprost, or tafluprost; or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: March 13, 2018
    Assignee: Manistee Partners LLC
    Inventors: Robert L. Bratzler, Martin Wand, Frederick Ryckman, Bradford J. Shingleton
  • Patent number: 9908870
    Abstract: The present invention relates to a novel crystalline form of a benzimidazole derivative and a preparation method thereof. The novel crystalline form according to the present invention is hardly changed chemically and/or physically under a long-term photo-stressed condition, has a low hygroscopicity, and has an extremely low static-electricity-inducing capability, thus being advantageous for formulation, and due to the excellent stability of the crystal form itself, it is very useful for long-term storage of the compound.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: March 6, 2018
    Assignee: CJ HEALTHCARE CORPORATION
    Inventors: Young Ju Kim, Eun Sun Kim, Ji Yun Lee, Hyuk Woo Lee, Jae Hong Kweon, Sung Ah Lee, Kwang Do Choi, Dong Hyun Ko, Seung Pyeong Heo
  • Patent number: 9902696
    Abstract: Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: February 27, 2018
    Assignee: Cephalon, Inc.
    Inventors: Nadine C. Becknell, Reddeppa Reddy Dandu, Bruce D. Dorsey, Dimitar B. Gotchev, Robert L. Hudkins, Linda Weinberg, Craig A. Zificsak, Allison L. Zulli
  • Patent number: 9902688
    Abstract: The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition Syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by Syk kinase activity, such as Non Hodgkin's Lymphoma.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: February 27, 2018
    Assignee: PORTOLA PHARMACEUTICALS, INC.
    Inventors: Zhaozhong J. Jia, Yonghong Song, Qing Xu, Brian Kane, Shawn M. Bauer, Anjali Pandey
  • Patent number: 9895372
    Abstract: The present invention relates to solid pharmaceutical compositions comprising biopterin derivatives as well as methods for obtaining such solid pharmaceutical compositions. The invention also relates to the solid pharmaceutical compositions of the invention for treating diseases.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: February 20, 2018
    Assignee: VASOPHARM GMBH
    Inventors: Peter Scheurer, Frank Tegtmeier, Reinhard Schinzel
  • Patent number: 9895309
    Abstract: A topical composition for skin repair comprising selenosugars of formula (1): (Formula (I)) wherein, n is 1, 2 or 3; m is 2, 3, 4; or 5; and each R1 is independently-(optionally substituted C1-C3 alkyiene)p-OH, where p is 0 or 1 or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: February 20, 2018
    Assignee: SELENO THERAPEUTICS PTY LTD.
    Inventors: Carl Herbert Schiesser, Corin Storkey, Michael Jonathon Davies
  • Patent number: 9890153
    Abstract: Compounds according to Formulas I, IA or IB: to pharmaceutically acceptable composition, salts thereof, their synthesis and their use as SIK2 inhibitors including such compounds and methods of using said compounds in the treatment of various diseases and/or disorders such as cancer, stroke, cardiovascular, obesity and type II diabetes.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: February 13, 2018
    Assignee: ARRIEN PHARMACEUTICALS LLC
    Inventors: Hariprasad Vankayalapati, Venkatakrishnareddy Yerramreddy, Venu Babu Ganipisetty, Sureshkumar Talluri, Rajendra P Appalaneni
  • Patent number: 9879058
    Abstract: The present invention is related to the use of compounds or pharmaceutically acceptable salts thereof that modulate astrocytic release of substances through connexin and pannexin hemichannels, for the treatment of psychiatric disorders. Compounds or pharmaceutically acceptable salts thereof used in the present invention comprise any compound that differentially modulates, blocks, opens, inhibits, and/or activates connexin and/or pannexin hemichannels from astrocytes while not affecting gap junctions. The invention is also related to a method for treating psychiatric disorders, comprising administering to a mammal or human a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, that modulates astrocytic release of substances through connexin and pannexin hemichannels. Pharmaceutical compositions and a screening method are also considered in the present invention.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: January 30, 2018
    Assignees: Universidad Andres Bello, Universiteit Gent, Katholieke Universiteit Leuven, Ku Leuven R & D
    Inventors: Jimmy Stehberg Liberman, Luc Gilbert Leybaert Sinia, Geert Albert Bultynck Demets, Mauricio Antonio Retamal Lucero, Fernando Danilo Gonzalez Nilo
  • Patent number: 9872493
    Abstract: The present invention provides a method for promoting plant growth, which comprises treating a plant with a compound represented by the following Formula (1): provided that a method for promoting plant growth which comprises treating plants with a compound corresponding to the following (1) or an agriculturally acceptable salt thereof are excluded, (1) benzo[b]thiophene-3-carboxylic acid. The method set forth in one of the above, the plant being soybeans. The method set forth in one of the above, the plant being cotton. A plant seed resulting from treatment with the compound of claim 1 containing an effective quantity of the compound indicated in formula (1). A composition for promoting plant growth and containing an inert component and the compound indicated in formula (1).
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: January 23, 2018
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Fujio Mukumoto, Hiroaki Tamaki, Shintaro Kusaka, Mitsuhiko Iwakoshi
  • Patent number: 9861603
    Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: January 9, 2018
    Assignee: LEO Laboratories Limited
    Inventors: Marc Barry Brown, Michael Edward Donald Crothers, Tahir Nazir
  • Patent number: 9833429
    Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: December 5, 2017
    Assignee: LEO Laboratories Limited
    Inventors: Marc Barry Brown, Michael Edward Donald Crothers, Tahir Nazir
  • Patent number: 9833428
    Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: December 5, 2017
    Assignee: LEO Laboratories Limited
    Inventors: Marc Barry Brown, Michael Crothers, Tahir Nazir
  • Patent number: 9828385
    Abstract: The present invention provides spiro-oxazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: November 28, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Cosimo Dolente, Bernhard Fasching, Valerie Runtz-Schmitt, Patrick Schnider
  • Patent number: 9820959
    Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: November 21, 2017
    Assignee: LEO Laboratories Limited
    Inventors: Marc Barry Brown, Michael Edward Donald Crothers, Tahir Nazir
  • Patent number: 9817001
    Abstract: Disclosed is a personalized diagnostic and treatment solution for cardiovascular disease. The invention comprises methods for devising a personalized treatment plan for a patient via the use of an extended CVD risk assessment panel measuring markers of cholesterol absorption and production and HDL subfractions. This solution provides a more complete risk assessment of an individual than merely measuring traditional CVD risk markers alone, and enables the healthcare practitioner to optimize therapy for patients with or without established CVD. This solution presents the advantages of greater accuracy, savings in time and cost over existing testing and treatment methods.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: November 14, 2017
    Assignee: BOSTON HEART DIAGNOSTICS CORPORATION
    Inventors: Bela F. Asztalos, Ernst J. Schaefer